Lilly's challenge is based on its patent case regarding the ADHD
drug atomoxetine (2010 FC 915, 2011 FCA 220).
In particular, Eli Lilly claimed that the development of the «promise doctrine» in Canadian patent law led to the invalidation of patents protecting
its drugs atomoxetine (Strattera ®) and olanzapine (Zyprexa ®) by Canadian courts, and that this doctrine was radically new, arbitrary, and discriminatory against pharmaceutical companies.
Not exact matches
There is an alternative, however:
Atomoxetine, known by its brand name, Strattera, is the only nonstimulant ADHD
drug sold in the United States — and the first ADHD
drug to be approved specifically for adults, in 2002.
In 2002, the FDA approved the first nonstimulant
drug for ADHD,
atomoxetine (known by its brand name, Strattera).
However, only two
drugs, long - acting methylphenidate and the non-stimulant
atomoxetine, are currently approved for the treatment of ADHD in Japan [13].